GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (LTS:0A8I) » Definitions » FCF Margin %

Genprex (LTS:0A8I) FCF Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Genprex FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Genprex's Free Cash Flow for the three months ended in Sep. 2024 was $-2.19 Mil. Genprex's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Genprex's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Genprex's current FCF Yield % is -298.25%.

The historical rank and industry rank for Genprex's FCF Margin % or its related term are showing as below:


LTS:0A8I's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -135.76
* Ranked among companies with meaningful FCF Margin % only.


Genprex FCF Margin % Historical Data

The historical data trend for Genprex's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex FCF Margin % Chart

Genprex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
Get a 7-Day Free Trial Premium Member Only - - - - -

Genprex Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genprex's FCF Margin %

For the Biotechnology subindustry, Genprex's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genprex's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genprex's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Genprex's FCF Margin % falls into.



Genprex FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Genprex's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-24.81/0
= %

Genprex's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-2.186/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genprex FCF Margin % Related Terms

Thank you for viewing the detailed overview of Genprex's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genprex Business Description

Traded in Other Exchanges
Address
3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Genprex Headlines

No Headlines